When is big pharma no longer big pharma?
After a bruising few months for GSK, 17 global drug makers now have a higher market cap than the UK company.
Ash 2022 preview – a new multiple myeloma mechanism makes a splash
Talquetamab gets top billing in Ash’s press programme, but the data raise important issues about the role of targeting GPRC5D.
Ash 2022 preview – Affimed and Aptose score
In oncology settings outside multiple myeloma investors have picked two early winners.
Abbvie grabs an antibody against an elusive target
Bristol Myers Squibb has been trying for years to hit LPA1 with small molecules, but an acquisition by Abbvie signals a new approach.
The gloom deepens for biopharma stocks
With most glimmers of hope extinguished in the third quarter, 2022 is shaping up to be an annus horribilis for sector share prices.
